drugset / Trial / NCT02307240
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.
Timeline
- Start
- 2014-11
- Primary completion
- 2019-05-31
- Completion
- 2019-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fimepinostat | Small molecule | 60 mg | Oral |